# Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

> **NCT05400070** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 45 (actual)

## Conditions studied

- Sintilimab
- Lung Cancer
- Anlotinib
- Chemotherapy

## Interventions

- **DRUG:** Neoadjuvant therapy 1

## Key facts

- **NCT ID:** NCT05400070
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400070, "Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05400070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*